SAB Biotherapeutics, Inc.
SABS
$3.94
-$0.21-5.06%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 138.92% | 141.13% | 8.10% | 14.02% | 19.17% |
| Total Depreciation and Amortization | -35.70% | -37.31% | -33.49% | -25.39% | 27.96% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -2,052.98% | -1,979.68% | -71.96% | -140.13% | -124.36% |
| Change in Net Operating Assets | -60.31% | 307.45% | 150.06% | 133.05% | -198.83% |
| Cash from Operations | -30.57% | 1.77% | 17.01% | 8.54% | -36.52% |
| Capital Expenditure | -176.67% | 84.16% | 53.49% | 31.74% | -71.04% |
| Sale of Property, Plant, and Equipment | -- | -- | -98.88% | -98.88% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -938.91% | -426.46% | 191.20% | 177.73% | -- |
| Cash from Investing | -917.42% | -418.09% | 189.13% | 176.43% | -7,728.66% |
| Total Debt Issued | -- | -32.57% | -32.57% | -32.57% | -32.57% |
| Total Debt Repaid | 70.60% | 54.34% | -36.47% | -29.40% | -23.13% |
| Issuance of Common Stock | 827,006.86% | 182.73% | -100.00% | -100.00% | -99.97% |
| Repurchase of Common Stock | 54.62% | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 99.69% | 100.00% | 89.41% | 44.03% | -- |
| Cash from Financing | 14,453.90% | 154.44% | -101.21% | -101.43% | -101.76% |
| Foreign Exchange rate Adjustments | 11.48% | -258.99% | -206.63% | -1,570.59% | -1,432.60% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 103.37% | 200.24% | -243.12% | -961.70% | -214.81% |